In cohort B of the international phase II KEYNOTE-086 study, pembrolizumab as first-line treatment for metastatic TNBC patients with tumor PD-L1 combined positive score (CPS) ≥1 was evaluated with PD-L1 22C3 pharmDx assay. This evidence concerns the gene CD274 and neoplasm.